Merck Total Long Term Liabilities 2010-2024 | MRK

Merck total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • Merck total long term liabilities for the quarter ending September 30, 2024 were $43.386B, a 2.49% increase year-over-year.
  • Merck total long term liabilities for 2023 were $43.346B, a 11.54% increase from 2022.
  • Merck total long term liabilities for 2022 were $38.863B, a 10.79% decline from 2021.
  • Merck total long term liabilities for 2021 were $43.565B, a 12.12% increase from 2020.
Merck Annual Total Long Term Liabilities
(Millions of US $)
2023 $43,346
2022 $38,863
2021 $43,565
2020 $38,857
2019 $36,176
2018 $33,549
2017 $34,689
2016 $37,865
2015 $37,709
2014 $30,979
2013 $35,451
2012 $32,321
2011 $31,940
2010 $33,335
2009 $35,188
Merck Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $43,386
2024-06-30 $42,922
2024-03-31 $40,326
2023-12-31 $43,346
2023-09-30 $42,333
2023-06-30 $42,333
2023-03-31 $37,760
2022-12-31 $38,863
2022-09-30 $39,559
2022-06-30 $40,609
2022-03-31 $43,399
2021-12-31 $43,565
2021-09-30 $33,903
2021-06-30 $35,394
2021-03-31 $37,447
2020-12-31 $38,857
2020-09-30 $40,125
2020-06-30 $40,693
2020-03-31 $35,130
2019-12-31 $36,176
2019-09-30 $35,722
2019-06-30 $36,143
2019-03-31 $36,141
2018-12-31 $33,549
2018-09-30 $33,888
2018-06-30 $34,146
2018-03-31 $35,180
2017-12-31 $34,689
2017-09-30 $33,710
2017-06-30 $34,334
2017-03-31 $36,650
2016-12-31 $37,865
2016-09-30 $38,823
2016-06-30 $38,111
2016-03-31 $37,286
2015-12-31 $37,709
2015-09-30 $37,970
2015-06-30 $38,436
2015-03-31 $39,986
2014-12-31 $30,979
2014-09-30 $30,521
2014-06-30 $31,416
2014-03-31 $33,426
2013-12-31 $35,451
2013-09-30 $38,198
2013-06-30 $38,369
2013-03-31 $31,792
2012-12-31 $32,321
2012-09-30 $32,506
2012-06-30 $30,940
2012-03-31 $31,613
2011-12-31 $31,940
2011-09-30 $32,345
2011-06-30 $32,510
2011-03-31 $33,364
2010-12-31 $33,335
2010-09-30 $32,469
2010-06-30 $33,084
2010-03-31 $34,795
2009-12-31 $35,188
2009-09-30 $15,364
2009-06-30 $15,163
2009-03-31 $11,126
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94